Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arena’s Lorcaserin Can Continue To Bloom In Phase III Obesity Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Safety monitoring board review of echocardiographic data gives firm a green light to continue with pivotal trial.

You may also be interested in...



Amylin Obesity Combo Scores Big Weight Loss In Phase IIa Trial

Subjects taking pramlintide/metreleptin lost a significant 12.7 percent of body weight compared with 8.4 percent for subjects on pramlintide alone.

Amylin Obesity Combo Scores Big Weight Loss In Phase IIa Trial

Subjects taking pramlintide/metreleptin lost a significant 12.7 percent of body weight compared with 8.4 percent for subjects on pramlintide alone.

Sanofi Withdraws Zimulti NDA For Weight Loss

Company cites confusion over concerns raised by the Endocrinologic and Metabolic Drugs Advisory Committee, which voted against approval June 13.

Related Content

Topics

UsernamePublicRestriction

Register

PS066582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel